35263-73-1

Basic information

• Product Name: LHRH
• Synonyms: gly(10)-lhr;PYROGLU-HIS-TRP-SER-TYR-GLY-LEU-ARG-PRO-GLY;PYR-HIS-TRP-SER-TYR-GLY-LEU-ARG-PRO-GLY;PYR-HIS-TRP-SER-TYR-GLY-LEU-ARG-PRO-GLY-OH;PYR-HWSYGLRPG;PGLU-HIS-TRP-SER-TYR-GLY-LEU-ARG-PRO-GLY;LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH), HUMAN;LUTEINIZING HORMONE-RELEASING HORMONE
• CAS NO: 35263-73-1
• Molecular Formula: C55H74N16O14
• Molecular Weight: 1183.27
• Product Categories: peptide
• Mol File: 35263-73-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: WHITE POWDER
• Density: 1.54 g/cm³
• Refractive Index: 1.709
• Storage Temp.: −20°C
• CAS DataBase Reference: LHRH(CAS DataBase Reference)
• NIST Chemistry Reference: LHRH(35263-73-1)
• EPA Substance Registry System: LHRH(35263-73-1)

Safety Data

• Hazard Codes: T
• Statements: 60
• Safety Statements: 53-22-36/37/39-45
• WGK Germany: 3
• Hazardous Substances Data: 35263-73-1(Hazardous Substances Data)

Usage

General Description

Luteinizing hormone-releasing hormone (LHRH), also known as Gonadotropin-releasing hormone (GnRH), is a peptide hormone that regulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. It is produced by the hypothalamus and plays a critical role in the control of reproductive function. LHRH is involved in the regulation of the menstrual cycle, ovulation, and the production of sex hormones in both men and women. In addition, it has been used medically in the treatment of hormone-sensitive cancers, such as prostate cancer and breast cancer, through the use of LHRH analogs to ultimately suppress the production of sex hormones in the body.

InChI:InChI=1/C55H74N16O14/c1-29(2)19-38(49(80)66-37(9-5-17-59-55(56)57)54(85)71-18-6-10-43(71)53(84)62-26-46(76)77)65-45(75)25-61-47(78)39(20-30-11-13-33(73)14-12-30)67-52(83)42(27-72)70-50(81)40(21-31-23-60-35-8-4-3-7-34(31)35)68-51(82)41(22-32-24-58-28-63-32)69-48(79)36-15-16-44(74)64-36/h3-4,7-8,11-14,23-24,28-29,36-43,60,72-73H,5-6,9-10,15-22,25-27H2,1-2H3,(H,58,63)(H,61,78)(H,62,84)(H,64,74)(H,65,75)(H,66,80)(H,67,83)(H,68,82)(H,69,79)(H,70,81)(H,76,77)(H4,56,57,59)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1

Upstream product

• 35661-60-0 Fmoc-Leu-OH 
• 98930-01-9 Nα-(9-fluorenylmethoxycarbonyl)-Nγ-(4-methoxy-2,3,6-trimethylbenzenesulphonyl)-L-arginine 
• 115057-30-2 {4-[[(S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-methyl-butyrylamino]-(4-methoxy-phenyl)-methyl]-2-methyl-phenoxy}-acetic acid 
• 71989-31-6 Fmoc-Pro-OH 
• 33515-09-2 gonadotropin releasing hormone 
• 4530-20-5 BOC-glycine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 13836-37-8 Boc-Arg(Tos)-OH 

Relevant articles and documents

Hydrolytic cleavage of pyroglutamyl-peptide Bond. V. Selective removal of pyroglutamic acid from biologically active pyroglutamylpeptides in high concentrations of aqueous methanesulfonic acid

Application of aqueous methanesulfonic acid (MSA) for selective chemical removal of pyroglutamic acid (pGlu) residue from five biologically active pyroglutamyl-peptides (pGlu-X-peptides, X=amino acid residue at position 2) was examined. Gonadotropin releasing hormone (Gn-RH), dog neuromedin U-8 (d-NMU-8), physalaemin (PH), a bradykinin potentiating peptide (BPP-5a) and neurotensin (NT) as pGlu-X-peptides were incubated in either 70% or 90% aqueous MSA at 25°C. HPLC analysis of the incubation solutions showed that the main decomposition product was H-X-peptide derived from each pGlu-X-peptide by the removal of pGlu. The results revealed that the pGlu-X peptide bond had higher susceptibility than various internal amide bonds in the five peptides examined, including the Trp-Ser bond in Gn-RH, the C-terminal Asn-NH2 in d-NMU-8, and the Asp-Pro bond in PH, whose acid susceptibility is well known. Thus, mild hydrolysis with high concentrations of aqueous MSA may be applicable to chemically selective removal of pGlu from pGlu-X-peptides for structural examinations.

PREPARATION AND APPLICATION OF NEW ACID LABILE ANCHOR GROUPS FOR THE SYNTHESIS OF PEPTIDE AMIDES BY FMOC SOLID PHASE SYNTHESIS

The synthesis and application of new linkage agents for the preparation of peptide amides using a modified Fmoc strategy is described.